Finanzen von Gain Therapeutics Inc (GANX)GANXGain Therapeutics Inc

Evaluating the bottom line, Gain Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -268.30%, provide a clear picture of how effectively GANX converts its operational activities into shareholder value.

In the context of the broader market, GANX competes directly with industry leaders such as LONA and IMA. With a market capitalization of $44.07M, it holds a significant position in the sector. When comparing efficiency, GANX's gross margin of N/A stands against LONA's N/A and IMA's N/A. Such benchmarking helps identify whether Gain Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company reported a narrower loss of $4.67 million in Q2 2026, compared to $5.81 million in Q2 2025, indicating improved cost management. The EPS for Q2 2026 was -0.11, showing a decrease from -0.19 in Q2 2025.